<DOC>
	<DOCNO>NCT00478322</DOCNO>
	<brief_summary>Purpose : A 28-day US study patient type 2 diabetes mellitus assess safety tolerability well effect treatment investigational drug .</brief_summary>
	<brief_title>Pharmacodynamic Study Effect INCB013739 Insulin Sensitivity Obese , Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Have establish diagnosis Type 2 Diabetes determine investigator . 2 . Females postmenopausal least 1 year document FSH &gt; 30 IU/L . 1 . Hypertriglyceridemia &gt; 500 mg/dL screening . 2 . BMI &gt; 40 kg/m2 . 3 . Receiving thiazolidinediones , insulin , exenatide within 3 month prior screen . 4 . History clinical manifestation Addison 's disease , Cushing 's Syndrome , disorder involve glucocorticoid mineralocorticoid . 5 . Current treatment treatment within 30 day five halflives ( whichever longer ) prior first dose study medication another investigational medication current enrollment another investigational protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes ;</keyword>
	<keyword>Type II diabetes ;</keyword>
	<keyword>Non-insulin dependent diabetes ;</keyword>
	<keyword>Obesity</keyword>
</DOC>